Morgan Stanley
GPCR icon

Morgan Stanley’s Structure Therapeutics GPCR Stock Holding History

Morgan Stanley’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151M Buy
2,806,640
+501,183
+22% +$22.2M 0.01% 1236
2026
Q1 		$111M Buy
2,305,457
+217,623
+10% +$14.9M 0.01% 1357
2025
Q4 		$145M Buy
2,087,834
+1,510,093
+261% +$61.7M 0.01% 1145
2025
Q3 		$16.2M Sell
577,741
-339,605
-37% -$6.76M ﹤0.01% 3085
2025
Q2 		$19M Buy
917,346
+224,907
+32% +$4.95M ﹤0.01% 2860
2025
Q1 		$12M Buy
692,439
+305,263
+79% +$7.48M ﹤0.01% 3179
2024
Q4 		$10.5M Buy
387,176
+224,690
+138% +$7.97M ﹤0.01% 3368
2024
Q3 		$7.13M Buy
162,486
+30,195
+23% +$1.17M ﹤0.01% 3681
2024
Q2 		$5.2M Sell
132,291
-161,342
-55% -$6.63M ﹤0.01% 3837
2024
Q1 		$12.6M Buy
293,633
+6,564
+2% +$277K ﹤0.01% 3154
2023
Q4 		$11.7M Buy
287,069
+263,255
+1,105% +$15.1M ﹤0.01% 3199
2023
Q3 		$1.2M Buy
+23,814
New +$767K ﹤0.01% 4691
2023
Q2 		– Sell
-11
Closed -$262 – 7678
2023
Q1 		$262 Buy
+11
New +$258 ﹤0.01% 7499

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley's GPCR Position: Q2 2026 in Review

Morgan Stanley increased its Structure Therapeutics (GPCR) stake by 22% in Q2 2026, buying an estimated $22.2M and bringing the position to 2,806,640 shares worth $151M. The position accounts for 0.01% of the portfolio, ranked #1236.

Morgan Stanley first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Morgan Stanley held 2,806,640 shares of Structure Therapeutics worth $151M as of Q2 2026.
  • Morgan Stanley bought 501,183 Structure Therapeutics shares in Q2 2026, an estimated $22.2M.
  • Structure Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1236 holding.
  • Morgan Stanley first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.